A 28-year-old woman from Mumbai with known HIV infection (CD4 count 150 cells/μL, not on ART) presents with progressive headache, fever, and neck stiffness for 10 days. CSF analysis shows: protein 180 mg/dL, glucose 35 mg/dL (serum glucose 90 mg/dL), cell count 120/μL (80% lymphocytes), Gram stain negative, bacterial culture negative, India ink stain positive. What is the most appropriate next step in management?

Explanation

## Diagnosis: Cryptococcal Meningitis in Advanced HIV **Key Point:** India ink stain positivity in CSF with low glucose, elevated protein, and lymphocytic pleocytosis in a patient with CD4 <200 is diagnostic of cryptococcal meningitis (CM). This is a medical emergency requiring immediate antifungal therapy and ART initiation. ### CSF Profile in Cryptococcal Meningitis | Parameter | Cryptococcal Meningitis | Tuberculous Meningitis | Bacterial Meningitis | |-----------|------------------------|----------------------|---------------------| | Protein | Markedly elevated (100–500) | Elevated (100–500) | Elevated (100–1000) | | Glucose | Low (<45, CSF:serum <0.4) | Low (<45) | Very low (<40) | | Cell count | 20–500 (typically <200) | 100–500 | 1000–10000 | | Cell type | Lymphocytes | Lymphocytes | Neutrophils early | | Gram stain | Negative | Negative | Positive (50–90%) | | India ink | **Positive (60–80%)** | Negative | Negative | | Culture | Positive (90–100%) | Positive (50–80%) | Positive (70–90%) | **High-Yield:** India ink stain is positive in 60–80% of CM cases; negative stain does NOT rule out disease. Cryptococcal antigen (CrAg) in CSF and serum is >95% sensitive and specific. ### Pathophysiology 1. CD4 <100 cells/μL → severe immunosuppression 2. Cryptococcus neoformans inhalation (environmental exposure) → pulmonary colonization 3. Hematogenous dissemination → CNS invasion 4. Meningeal inflammation → elevated protein, low glucose (due to impaired glucose transport into CSF) 5. Minimal inflammatory response (few neutrophils) due to absent cellular immunity **Clinical Pearl:** Cryptococcal meningitis in advanced HIV often presents **insidiously** with subtle headache and fever over days to weeks, unlike bacterial meningitis which is acute. Neck stiffness may be absent in 25–50% of cases due to blunted inflammation. ### Management Algorithm ```mermaid flowchart TD A[India ink positive + CD4 &lt;200]:::outcome --> B[Confirm with CrAg serum/CSF]:::action B --> C[Start antifungal therapy]:::action C --> D[Induction: Amphotericin B IV + Fluconazole]:::action D --> E[Continue 2 weeks]:::action E --> F[Consolidation: Fluconazole 400-800 mg daily]:::action F --> G[Maintenance: Fluconazole until CD4 &gt;100 x 3 months]:::action G --> H[Initiate ART simultaneously or within 2 weeks]:::action H --> I[Monitor for IRIS]:::decision ``` **Mnemonic: CRYPTO CARE** — Confirm with antigen, Rapid antifungal start, Years of fluconazole (maintenance), Prevent relapse with CD4 recovery, Target CD4 >100, Optimize ART timing. ### Antifungal Regimen (Induction Phase) **First-line:** - **Amphotericin B deoxycholate** 0.7–1 mg/kg IV daily (or liposomal formulation if renal impairment) - **PLUS Fluconazole** 400–800 mg daily (or 10 mg/kg/day) - Duration: 2 weeks (or until CSF sterilization if delayed) **Consolidation Phase (weeks 3–10):** - Fluconazole 400–800 mg daily alone **Maintenance Phase (until CD4 >100 for ≥3 months):** - Fluconazole 200 mg daily ### ART Timing **High-Yield:** Start ART within 2 weeks of antifungal initiation (optimal: days 7–14). Early ART (within 2 weeks) improves outcomes and reduces mortality compared to delayed initiation, despite IRIS risk. **Warning:** Immune reconstitution inflammatory syndrome (IRIS) occurs in 10–30% of CM cases when CD4 recovers; manage with increased fluconazole dose ± corticosteroids. ### Why Immediate ART? - Restores CD4-mediated immunity → fungal clearance - Reduces mortality from 100% (untreated) to ~30–40% (with optimal therapy) - IRIS is manageable; untreated CM is fatal [cite:Harrison 21e Ch 197]